Miscellaneous Malignancies | Norton Healthcare

Indication: Miscellaneous Malignancies

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors

Sub-indication: Miscellaneous Malignancies

Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: Genmab

Learn more at ClinicalTrials.gov

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.